AKA. M. Kryvchun

A. M. Kryvchun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. M. Kryvchun has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Secondary hyperkalemic paralysis (clinical case)

    by M. Yu. Delva, I. I. Delva, V. A. Pinchuk, G. Ya. Sylenko, K. A. Tarianyk, K. V. Hryn, T. Yo. Purdenko, A. M. Kryvchun, A. D. Shkodina

    Background. Secondary hyperkalemic paralysis (SHP) is a specific and rare manifestation of hyperkalemia characterized by acute (subacute) symmetrical flaccid paresis. If SHP is not recognized promptly, the further progression of hyperkalemia can lead to the development of fatal cardiac arrhythmias and respiratory failure. Purpose – presentation of a clinical case of SHP. Materials and Methods. A clinical case of SHP in the form of transient lower paraplegia in a patient with newly diagnosed multiple myeloma complicated by acute nephropathy is reported. Results. A 53-year-old male patient was admitted to the emergency department complaining of a lack of movement in his lower limbs. About 6 hours ago, he suddenly experienced weakness in both lower limbs, and about 2 hours ago, movement in both legs disappeared. There is no active movement in both lower limbs, but muscle strength in the upper limbs is normal. Muscle tone in the upper limbs is normal, but significantly reduced in the lower limbs. Deep reflexes in the upper limbs are reduced and symmetrical, but absent in the lower limbs. No pyramidal symptoms, sensory and coordination disorders, meningeal symptoms were detected. ECG: sinus bradycardia 51/min, high-pointed T waves, widened QRS complexes. Biochemical blood analysis: creatinine – 3295.3 μmol/L (70–115), urea – 76.4 mmol/L (<8.3), potassium – 9.4 mmol/L (3.3–5.5), calcium – 3.07 mmol/L (2.15–2.55). On the same day, during acute hemodialysis, the patient began to move his lower limbs. The next day, strength in the legs was fully restored, and serum potassium was 6.05 mmol/L. Conclusions. In cases of acute (subacute) tetraparesis or lower paraparesis, SHP should be ruled out, especially in patients with kidney disease.

  • Open Access

    Chronic inflammatory axonal polyneuropathy (clinical case report, discussion)

    by M.YU. Delva, I.I. Delva, V.A. Pinchuk, K.A. Tarianyk, H.YA. Sylenko, T.Y. Purdenko, A.M. Kryvchun, K.V. Hryn

    The purpose was to demonstrate the significance of knowledge of diagnostic criteria for rare types of polyneuropathy among neurologists by describing a clinical case of chronic inflammatory axonal polyneuropathy. Female patient V., 51 years old, complained of unpleasant sensations in both feet and lower legs, weakness in the legs, and walking difficulties. She has been suffering for 4 months since she noticed burning sensations in her feet for no obvious reason. The patient has repeatedly sought medical help from family doctor, neurologists. She was diagnosed with idiopathic polyneuropathy of the lower extremities, for which repeatedly underwent outpatient and inpatient treatment. Despite this, discomfort in her feet increased, and she began to experience leg fatigue and walking difficulties. At the initial examination, peripheral lower distal moderate paraparesis, decreased pain and tactile sensitivity in the feet and the distal parts of the lower leg, impaired muscle-joint and vibration sensitivity in the toes were detected. Gait was paraparetic with ataxia. The following findings were revealed during additional examinations: high levels of cyanocobalamin in the blood (the patient was taking vitamin B12), primary axonal type of nerve fiber lesions by electroneuromyography, and elevated protein levels in the cerebrospinal fluid. Diagnosis was chronic inflammatory axonal polyneuropathy with mode­rate distal paraparesis of the lower extremities, sensory ataxia. The following treatment was prescribed: prednisolone 60 mg per day, omeprazole, and spironolactone. At the end of the second week of taking prednisolone, the patient noticed a decrease in unpleasant sensations in her legs and improved walking. After 2 months, the dysesthesia in her legs completely disappeared, muscle strength in the legs was restored, and walking was normalized. At the follow-up examination, full restoration of strength in the leg muscles, of muscle-joint sensation in the toes, and vibration sensitivity in the feet were noted. Neurologists need to be aware of and use diagnostic criteria for chronic inflammatory axonal polyneuropathy to ensure adequate treatment.